Concepedia

Silvia Chang

SC

Statistics

Publications

15

Citations

551

H-Index

12

Active since

2015

Affiliations

Gilead Sciences (United States)(Current)

Hôpital Beaujon

Inserm

Assistance Publique – Hôpitaux de Paris

Université Paris Cité

Silvia Chang is an author at Gilead Sciences (United States) specializing in antiviral therapy, molecular virology, and antiviral drug resistance.

Publications per year

2015–2024

15

Publications

15

Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification

Charlotte Hedskog, Bandita Parhy, Silvia Chang et al. · Open Forum Infectious Diseases · 2019 · 118 citations · Full text

, , +17

Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases

Michael K. Lo, César G. Albariño, Jason K. Perry et al. · Proceedings of the National Academy of Sciences · 2020 · 72 citations · Full text

, , +17

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Kristen Andreatta, Madeleine Willkom, Ross Martin et al. · Journal of Antimicrobial Chemotherapy · 2019 · 62 citations · Full text

, , +17

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection

Andrea L. Cathcart, Henry Lik‐Yuen Chan, Neeru Bhardwaj et al. · Antimicrobial Agents and Chemotherapy · 2018 · 60 citations · Full text

, , +17

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

Rima Acosta, Madeleine Willkom, Ross Martin et al. · Antimicrobial Agents and Chemotherapy · 2019 · 60 citations · Full text

, , +17

1–5 of 15